Latest News and Press Releases
Want to stay updated on the latest news?
-
MUNICH, Aug. 20, 2025 (GLOBE NEWSWIRE) -- Sono Group N.V. (OTCQB: SEVCF) (hereafter referred to as “Sono” or the “Company”, parent company to Sono Motors GmbH, hereafter referred to as “SonoSolar”...
-
MERIDIAN, Idaho, Aug. 14, 2025 (GLOBE NEWSWIRE) -- PCS Edventures!, Inc. (“PCSV”), a leading provider of TK-12 Science, Technology, Engineering and Mathematics (“STEM”) education programs, today...
-
Anzu-cel (anzutresgene autoleucel, IMA203) PRAME Cell Therapy: One-time infusion continues to show favorable tolerability as well as strong anti-tumor activity and durability in 33 heavily pretreated...
-
Capstone Infrastructure Corporation Reports Second Quarter Results and Declares a Quarterly Dividend
Toronto, Ontario, Aug. 07, 2025 (GLOBE NEWSWIRE) -- Capstone Infrastructure Corporation (TSX: CSE.PR.A) (the "Corporation" or "Capstone") today announced and filed its financial results for the...
-
LAKEWOOD, Colo., July 31, 2025 (GLOBE NEWSWIRE) -- FirstBank, one of the nation’s largest privately held banks with a focus on “banking for good,” announced its 2025 second-quarter summary of the...
-
VANCOUVER, British Columbia, May 30, 2025 (GLOBE NEWSWIRE) -- SHARC International Systems Inc. (CSE: SHRC) (FSE: IWIA) (OTCQB: INTWF) ("SHARC Energy" or the “Company”) is pleased to announce it has...
-
FirstFarms’ Q1-resultat blev ikke som oprindeligt forventet Lave grisepriser i begyndelsen af Q1, mindre effekt fra værdireguleringer, engangsomkostninger samt udbrud af mund- og klovesyge (FMD) på...
-
FirstFarms’ Q1 result was not as originally expected Low pig prices at the beginning of Q1, lower impact from value adjustments and outbreak of foot and mouth disease (FMD) on the Group’s largest...
-
Toronto, Ontario, May 13, 2025 (GLOBE NEWSWIRE) -- Capstone Infrastructure Corporation (TSX: CSE.PR.A) (the "Corporation" or "Capstone") today announced and filed its financial results for the first...
-
IMA203 PRAME Cell Therapy: Randomized-controlled Phase 3 trial, SUPRAME, in previously treated advanced melanoma ongoing and expected to complete enrollment in 2026IMA203 PRAME Cell Therapy: Phase 1b...